logo-loader
viewImugene Ltd

Imugene in trading halt with capital raising news pending

The company’s securities are in a trading halt until Monday, December 2, or when an announcement is made to the market.

Imugene Ltd - Imugene in trading halt with capital raising pending
Imugene is developing drugs that seek to activate the immune system of cancer patients

Imugene Limited (ASX:IMU) has been granted a trading halt by the ASX with an announcement pending in relation to a proposed capital raising.

The trading halt will remain in place until the beginning of normal trading on Monday, December 2, 2019, or when an announcement is released to the market, whichever occurs earliest.

Imugene's securities last traded at 4.4 cents after reaching a new 12-month high of 6.3 cents on November 22.

Two separate phase-I clinical trials

Earlier this month the company recently revealed plans to conduct two separate phase-I clinical trials in 2020 to test two constructs of the CF 33 oncolytic virus (OV).

One version of the OV is “armed” with an immune checkpoint inhibitor inserted in the virus, which is known as CheckVacc.

The second is an unarmed construct known as Vaxinia.

Both constructs have completed clinical-grade GMP batches at the City of Hope Cenrtre for Biomedicne and Genetics (CBG).

Quick facts: Imugene Ltd

Price: 0.055 AUD

ASX:IMU
Market: ASX
Market Cap: $239.79 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Imugene gets green light to start phase-1 clinical trial of new cancer...

Imugene Ltd's (ASX:IMU) Leslie Chong speaks to Proactive's Andrew Scott following the news it's received a second Human Research Ethics Committee approval to begin a phase-I clinical trial of its cancer checkpoint immunotherapy candidate, PD1-Vaxx. Ethics approval is confirmation that Imugene...

3 weeks, 2 days ago

2 min read